Salute e Benessere

ZINZINO AB (PUBL.): ANNUAL REPORT ENGLISH 2022

For more information please contact : For more information please contact: Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25 700, email:dag@zinzino.com Fredrik Nielsen CFO Zinzino +46 707 900 174, email:fredrik.nielsen@zinzino.com Images for free publication :marketing@zinzino.com Certified Adviser:Erik Penser Bank Aktiebolag, +46 (0) 8 463 83 00, email:certifiedadviser@penser.se The following files are available for download: View original content:...
PR Newswire
08/06/2023

Telesis Bio to Present at Jefferies Healthcare Conference 2023

/ 7:00 am Pacific Time. The live and archived webcast of the presentation will be accessible from the company's website athttps://ir.telesisbio.com/news-events/events. The replay of the webcast will be available for 90 days. About Telesis BioTelesis Bio is empowering scientists with the ability to create novel, synthetic biology-enabled solutions for many of humanity's greatest challenges. As inventors of the industry-standard Gibson Assembly ®method and the first commercial...
Nasdaq GlobeNewswire
08/06/2023

PAP Adherence Lowers ER Visits 24-36% in 1 Year for People with Sleep Apnea and…

The studies also showed 18-40% lower costs incurred from ER visits and hospitalizations after 1 year for PAP-adherent OSA patients with diastolic and systolic heart failure, respectively A third study estimates over 200 million women have mild obstructive sleep apnea worldwideINDIANAPOLIS, June08, 2023(GLOBE NEWSWIRE) -- People with heart failure and obstructive sleep apnea (OSA) can significantly reduce hospitalizations and ER visits as well as related costs by being adherent on...
Nasdaq GlobeNewswire
08/06/2023

Enochian BioSciences Announces that its Cancer Platform Remains on Track for…

(NASDAQ: ENOB). Enochian BioSciences Inc. (the Company) announces that it remains confident in submitting an Investigational New Drug Application (IND) for its innovative Cancer Platform in early/mid 2024 following review of comments made by the US Food and Drug Administration on the Company's Pre-IND submission. If successful, that would allow clinical trials to begin by the first half of 2024. The Company's proprietary, novel technology uses cell- and gene-therapy to promote a renewed...
Nasdaq GlobeNewswire
08/06/2023

Ultimovacs ASA: Mandatory notification of trade by primary insider

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act. Attachment 20230608 - Ultimovacs Notification of trade - Langoya Invest KRT-1500
Nasdaq GlobeNewswire
08/06/2023

Telix Opens European Radiopharmaceutical Production Facility

Radiopharmaceuticals use targeting agents (small molecules or antibodies) to deliver targeted radiation to cancer cells, regardless of where the cancer is in the body. These agents can be used for imaging (diagnosis) or therapy. Often referred to as "theranostics", this approach has the potential to better inform treatment decisions and deliver personalised therapy for patients. Radiopharmaceuticals use targeting agents (small molecules or antibodies) to deliver targeted radiation to…
PR Newswire
08/06/2023

DNAnexus® Applauded by Frost & Sullivan for Supporting Better Clinical…

DNAnexus offers a range of cutting-edge solutions to address the complex challenges of genomics research and clinical pipelines. DNAnexus® Titan, the company's next-generation sequencing (NGS) data management and analysis platform, powers genomics research and clinical pipelines with exceptional security, speed, and scalability. DNAnexus® Apollo, its multi-omics data science exploration, analysis, and discovery platform, releases the power of genomics and multi-omics in translational research…
PR Newswire
08/06/2023

Alkermes Publishes Investor Presentation Detailing Company's Transformation and…

Recommends Shareholders Vote "FOR" Alkermes' Board Nominees on Company's WHITE Proxy Card Recommends Shareholders Vote "FOR" Alkermes' Board Nominees on Company'sWHITEProxy Card DUBLIN,June 8, 2023/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) (the Company) today announced that it has filed an investor presentation with the U.S. Securities and Exchange Commission (SEC) in connection with the Company's upcoming 2023 annual general meeting of shareholders (the Annual Meeting)…
PR Newswire
08/06/2023

Breast Cancer Drugs Market to Reach $59.3 Billion, Globally, by 2032 at 8.4%…

Download Sample Report- https://www.alliedmarketresearch.com/request-sample/11488 Download Sample Report-https://www.alliedmarketresearch.com/request-sample/11488 Prime Determinants of Growth The global breast cancer drugs market is experiencing growth due to several factors, such as the rise in the prevalence of breast cancer cases, advancements in diagnostic technologies, and high investments in research and development. However, adverse effects of medications used for...
PR Newswire
08/06/2023

Ultimovacs ASA: Mandatory notification of trade by primary insider

This information is subject to the disclosure requirements pursuant to the Market Abuse Regulation article 19 and section 5-12 of the Norwegian Securities Trading Act. Attachment 20230608 - Ultimovacs Notification of trade - Radforsk KRT-1500
Nasdaq GlobeNewswire
08/06/2023

Global Lactobacillus Acidophilus Probiotics Market to Expand at a CAGR of 8.1%…

Download PDF Sample here: https://growthmarketreports.com/request-sample/5215 Download PDF Sample here: https://growthmarketreports.com/request-sample/5215 The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include type, application, and competitor analysis. This report also includes a complete analysis of...
PR Newswire
08/06/2023

Menarini Group Shares NEXPOVIO® (selinexor) Subgroup Data from BOSTON trial at…

"The data presented today emphasize the synergy between selinexor and bortezomib, highlighting the importance of a double mode of action switch. These results are particularly relevant considering the increased use of the daratumumab lenalidomide dexamethasone combination in clinical practice today," said Professor Maria-Victoria Mateos, MD, PhD, University Hospital Salamanca, Spain. "These findings further support the use of selinexor in combination with bortezomib in PI /…
PR Newswire
08/06/2023

Zerion Pharma's Dispersome® technology published in two peer-reviewed papers…

"We are extremely happy to collaborate with both Bayer and Novartis. It is a great opportunity for ZERION to apply our Dispersome® technology to their drug compounds and we are proud to see that our collaborations resulted in valuable insights and learnings for the further development of the technology. It goes without saying that we are thankful to both Bayer and Novartis for their openness to share these findings with the scientific community. Especially for new technologies such as the…
PR Newswire
08/06/2023

Nerve Repair and Regeneration Market to Reach $20.5 Billion by 2030: Grand View…

Read full market research report for more Insights, "Nerve Repair And Regeneration Market Size, Share & Trends Analysis Report By Surgery (Nerve Grafting, Neurorrhaphy), By Product (Biomaterials Neurostimulation & Neuromodulation Device), By Region, And Segment Forecasts, 2023 - 2030", published by Grand View Research. Read full market research report for more Insights, " Nerve Repair And Regeneration Market Size, Share & Trends Analysis Report By Surgery (Nerve…
PR Newswire
08/06/2023

HIVE FURNITURE SHOW ANNOUNCES ITS NEW EDITION, ATTRACTS OVER 180 GLOBAL…

To support sustainable furniture, this edition we will also host a webinar for all factories to guide them on how to apply sustainable practices across their operations. A tree will also be planted for each factory that will participate in the seminar in coordination with the authorised environmental entities. To support sustainable furniture, this edition we will also host a webinar for all factories to guide them on how to apply sustainable practices across their operations. A tree will…
PR Newswire
08/06/2023

Birmingham spinout to develop 20-minute test following surge in sexually…

The funding from the UK'sNational Institute for Health and Care Research (NIHR) will cover essential work to optimise and validate Linear's platform technology so it can diagnose infection from rectal and pharyngeal (throat) swabs. Gonorrhoea and Chlamydia are both major public health concerns. While Chlamydia remains the most commonly detected sexually transmitted infection in the UK, theUK Health Security Agency recently warned of a surge in gonorrhoea cases, and theWorld...
PR Newswire
08/06/2023

Maxima Grupė's solid BB+ credit rating affirmed by Standard & Poor's

According to Standard & Poor's, among the reasons for affirming the solid BB+ credit rating is the successful ongoing expansion of the Stokrotka retail chain in Poland, also strong market share in Baltics thanks to a competitive price position and high brand awareness. “S&P's decision to uphold Maxima Grupė's BB+ rating underscores the company's resilient performance and prudent financial management, even in the face of the global economic uncertainty that has unfolded in…
Nasdaq GlobeNewswire
08/06/2023

Inventiva and Echosens launch joint initiative to increase NASH awareness and…

Daix (France), Long Island City (New York, United States) / Paris (France) and Waltham (United States), June 8, 2023– Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (“NASH”) and other diseases with significant unmet medical needs and Echosens, a high-technology company providing a comprehensive range of...
Nasdaq GlobeNewswire
08/06/2023

Implantica Announces Completion of First RefluxStop™ procedures by the President…

"The procedures went exceptionally well. We were honored to host in our operating rooms Dr. Peter Forsell, a visionary surgeon and the entrepreneur behind this breakthrough surgical technology. We are excited to be at the forefront of implementing novel treatment methods, and RefluxStop's unique approach to restore natural anatomy offers great hope for the larger medical and patient communities," says Prof. Bonavina. "The procedures went exceptionally well. We were honored to host…
PR Newswire
08/06/2023

Nexstim provides overview of pilot study results in treatment of severe…

Press release, Helsinki, 8 June 2023 at 9 AM (EEST) Nexstim provides overview ofpilot study results in treatment of severe depression with Nexstim NBT® System at Kuopio University Hospital Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") provides an overview of results of the pilot study on the use of accelerated iTBS protocol in treatment of severe depression with Nexstim NBT® System at Kuopio University Hospital. The pilot study examined the use of accelerated...
Nasdaq GlobeNewswire
08/06/2023

Sandoz presents compelling investment proposition as standalone company at…

Sandoz well positioned to deliver continued mid-single digit sales growth; core EBITDA margin of 24-26% and Free Cash Flow to more than double over mid termEuropean champion committed to further extending global leadership in attractive and growing generics and biosimilars market, via purpose-driven strategy with focus on access and sustainabilitySix strategic levers to drive long-term investor value; attractive financial outlook, including targeted investment grade credit...
Nasdaq GlobeNewswire
08/06/2023

Continued strong Cresemba® (isavuconazole) sales by Pfizer trigger…

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, June 08, 2023 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial or fungal infections, reported today that sales of the antifungal Cresemba ®(isavuconazole) by its license partner Pfizer in Europe and the Asia Pacific and China regions, respectively, exceeded thresholds that triggered two separate milestone...
Nasdaq GlobeNewswire
08/06/2023

Mendus AB: Notice of Extraordinary General Meeting in Mendus AB (publ)

The shareholders of Mendus AB (publ) (the “ Company ”), reg. no 556629-1786, are hereby invited to the Extraordinary General Meeting (“ EGM ”) on Monday, 10 July 2023, at 09:30 a.m. at Tändstickspalatset, Västra Trädgårdsgatan 15, Stockholm. Registration for the meeting will commence at 09:00 a.m.NOTIFICATION Shareholders who wish to attend the meeting must: both be recorded in the share register maintained by Euroclear Sweden AB on the record date on Friday, 30 June 2023; and ...
Nasdaq GlobeNewswire
08/06/2023

Mendus AB: Mendus announces a directed share issue and a fully secured rights…

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL OR DEMAND ADDITIONAL REGISTRATION OR OTHER MEASURES. PLEASE REFER TO “IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE. As announced through a...
Nasdaq GlobeNewswire
08/06/2023
Altri  Comunicati